Liraglutide 1.8 mg daily evaluated for beta-cell function and safety in newly onset Type 1 Diabetes
Liraglutide in Newly Onset Type 1 Diabetes.
Abstract
Liraglutide 1.8 mg daily was investigated for 52 weeks as an adjunctive therapy to insulin to assess beta-cell function and safety in newly diagnosed Type 1 Diabetes.